Drug Profile
Research programme: HIV protease inhibitors - Cristalia
Alternative Names: CRS-074; CRS-075Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cristalia
- Class
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in Brazil
- 11 Feb 2009 Pharmacodynamics data from a preclinical trial in HIV infections presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI-2009)
- 25 Jul 2007 Preclinical trials in HIV infections treatment in Brazil (unspecified route)